Abbott Laboratories received FDA approval for its Volt™ PFA System to treat atrial fibrillation, a condition affecting 12 million Americans over 65. The approval strengthens Abbott’s cardiovascular portfolio and opens access to a growing AFib market. The company’s stock has gained 10.35% YTD but declined 8.15% in the past three months.

Abbott’s Q3 fiscal 2025 results showed revenue rising 6.9% YOY to $11.37 billion, in line with Wall Street estimates. Adjusted net earnings increased 7.5% to $2.3 billion, with strong growth in medical devices. The company reaffirmed its full-year 2025 outlook, expecting organic sales growth of 7.5%–8.0% and double-digit earnings growth.

Analysts have a positive outlook on Abbott, forecasting Q4 EPS to rise 11.9% YOY and full-year fiscal 2025 bottom line growth of 10.3%. The stock carries a “Strong Buy” consensus rating, with an average price target of $146.69 implying 17.8% upside potential. Management highlighted a strong product pipeline and investment in clinical trials as growth drivers.

Read more at Yahoo Finance: This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?